EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines

Sami Salmikangas, Iina Lindholm, Nasrin Sultana, Nanna Merikoski, Kirsi Toivanen, Xiaonan Liu, Markku Varjosalo, Tom Böhling, Tiina Vesterinen, Harri Sihto

Molecular & Cellular Proteomics · 2026-10 · 25 (10) · 101663

DOI: 10.1016/j.mcpro.2026.101663 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-10. Verfasst von Sami Salmikangas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address:…. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 3, Peptide Chain Initiation, Translational. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Jusélius Foundation, Research Council of Finland, Medical Association of Life and Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphodiesterase 3A (PDE3A) modulators such as anagrelide induce complex formation between PDE3A and Schlafen 12 (SLFN12), selectively killing cancer cells that co-express both proteins. As PDE3A forms isoform- and cell type-specific signalosome complexes across multiple subcellular compartments, the effects of its modulation are expected to depend strongly on the surrounding protein interaction network. However, despite considerable preclinical and early clinical interest in PDE3A modulators, the cellular context in which these compounds act has remained poorly characterized. Using proximity-dependent biotinylation in two human cancer cell lines (SA-4, liposarcoma; HeLa, cervical adenocarcinoma), we mapped the interactomes of PDE3A, SLFN12, and the anagrelide-induced PDE3A-SLFN12 complex. Anagrelide induced 259 high-confidence interactions, most notably with ribosomal proteins and translation initiation factors, while suppressing 877 interactions, most prominently those associated with the proteasome, protein folding, and the ER membrane. Interactions were selectively induced with peripheral eukaryotic translation initiation factor 3 (eIF3) subunits eIF3A and eIF3B, while interactions with core eIF3 subunits eIF3H, eIF3L, and eIF3M were suppressed. These findings were validated by native co-immunoprecipitation across three cancer cell lines, and multiplex immunofluorescence confirmed accumulation and ribosomal redistribution of both PDE3A and SLFN12 following anagrelide treatment. AlphaFold modeling of the PDE3A-SLFN12 complex with a partial 43S pre-initiation complex predicted binding near eIF3B and the eIF2αβγ-tRNA ternary complex at the mRNA entry channel. By mapping the interactomes surrounding the drug-induced complex, our study provides important mechanistic context for how PDE3A modulators act within the cell. In our proposed model, anagrelide remodels the interactome of the PDE3A-SLFN12 complex, which relocalizes and accumulates near the mRNA entry channel of the 43S pre-initiation complex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclic Nucleotide Phosphodiesterases, Type 3Peptide Chain Initiation, TranslationalHumansCell Line, TumorProtein Interaction MapsHeLa CellsProtein Binding

Stichwörter der Autor:innen

interactomicsmolecular gluesphosphodiesterase 3Aschlafen 12translation initiation

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 3PDE3A protein, human

Autor:innen und Institutionen

  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: sami.salmikangas@helsinki.fi.
  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki,…
  • Institute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
  • Rare Cancers Research Group, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; HUS Diagnostic Center, Department of Pathology, University of Helsinki and Helsinki Unive…
  • HUS Diagnostic Center, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Förderung

  • Sigrid Jusélius Foundation
  • Research Council of Finland
  • Medical Association of Life and Health
  • Outpatient Research Foundation
  • Relander Foundation sr
  • Mary and Georg C Ehrnrooth Foundation

Zitieren

APA

Salmikangas, S., Lindholm, I., Sultana, N., Merikoski, N., Toivanen, K., Liu, X., Varjosalo, M., Böhling, T., Vesterinen, T., & Sihto, H. (2026). Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines. Molecular & Cellular Proteomics, 25(10), 101663. https://doi.org/10.1016/j.mcpro.2026.101663

Vancouver

Salmikangas S, Lindholm I, Sultana N, Merikoski N, Toivanen K, Liu X, et al. Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines. Molecular & Cellular Proteomics. 2026;25(10):101663. doi:10.1016/j.mcpro.2026.101663

BibTeX
@article{Salmikangas2026,
  author = {Salmikangas, Sami and Lindholm, Iina and Sultana, Nasrin and Merikoski, Nanna and Toivanen, Kirsi and Liu, Xiaonan and Varjosalo, Markku and Böhling, Tom and Vesterinen, Tiina and Sihto, Harri},
  title = {Anagrelide Remodels the PDE3A–SLFN12 Interactome to Associate with Translation Initiation Machinery in Cancer Cell Lines},
  journal = {Molecular & Cellular Proteomics},
  year = {2026},
  volume = {25},
  number = {10},
  pages = {101663},
  doi = {10.1016/j.mcpro.2026.101663}
}
Kostenlos starten →